Basic information
Study ID
Trial registration number
language of publication
Country
Types of study
NOTE:
Study characteristics
Single or multicentre?
Participants
Number of participants
Diagnostic criteria of AKI
Age(mean, median, range)
Sex (male numbers/%)
Underlying cause of AKI
Pre‐existence of ESKD
Bleeding risk Elderly patients (> 60 years) Duration after major operation Presence of disseminated intravascular clotting (DIC) Liver disease Other risk Very high/High/Moderate/Low risk:
NOTE:
Baseline laboratory data
Baseline haemoglobin Baseline platelet count Baseline APTT Baseline PT‐INR Baseline ACT Baseline Ca Baseline Na Baseline arterial Blood pH
Dialysis
Number of circuits Types of CRRT Types of circuits Types of filters Catheter position Blood flow Dialysate flow Co‐intervention Filtration dose
Types of intervention
Types of intervention Types of comparison Target APTT Target ACT Target PT‐INR Antiplatelet use
NOTE:
Results (number of people)
Primary outcomes Major bleeding Incidence of major bleeding, defined as bleeding requiring blood transfusion, or as defined by the authors Successful prevention of clotting Successful prevention of clotting is defined as no need of circuit change in the first 24 hours for any reason Death Death from any cause at days 28
Secondary outcomes Early termination with blood loss in the circuits Early termination is defined as the full prescribed dose is not administered in the first 24 hours for any reason Blood loss is defined as impossible return of participants' own blood to them from circuits for any reason Thrombotic event Incidence of catheter malfunction presumed due to thrombosis defined as a failure to achieve a blood flow despite positional changes of the patient and additional saline flush or both, or as defined by the study authors Recovery of kidney function Numbers of participants free of RRT after discontinuing CRRT at days 28 Thrombocytopenia Thrombocytopenia defined as an emergent platelet count < 150,000/µL (150 x 109/L) after starting CRRT, or as defined by the study authors Adverse events Numbers of participants who dropped out because of adverse events (technique or participants dependent factors) Numbers of patients experiencing any adverse events Hypocalcaemia Hypocalcaemia, defined as defined by the study authors Hypercalcaemia Hypercalcaemia as defined by the study authors Hypernatraemia Hypernatraemia as defined by the study authors Metabolic disturbances Metabolic disturbances, such as acidosis or alkalosis as defined by the study authors Other adverse events Other adverse events including allergic reactions, urticaria and anaphylaxis Cost to health care services types and number of dialyser filters and circuits use/no use of anticoagulation types of anticoagulation
Other information
Dropouts Numbers of participants who dropped out for any reason
NOTE:
Additional information
Conflict of interest Financial support Other possible conflict of interest
NOTE: